Celltrion Inc (068270) · Trading Issue

Hanwha Corp (000880) · Trading Issue

Trading suspension for Hanwha Corp shares is scheduled to begin on 2026-07-30 in connection with the corporate spin-off, with trading expected to resume on 2026-08-25 upon relisting of Hanwha Corp and listing of the spun-off entity.

7/30/2026, 12:00:00 AM

Hanwha Corp (000880) · Trading Issue

Hanwha Corp confirmed a corporate spin-off creating Hanwha Machinery & Service Holdings (tentative name), separating the tech and life solutions businesses from the surviving Hanwha Corp, which will retain defense, energy, finance and related core businesses. The action also entails a scheduled trading suspension and distribution of new shares to existing holders.

7/30/2026, 12:00:00 AM

HLB Co Ltd (028300) · Other

The U.S. FDA's final decision on the New Drug Application (NDA) for the Rivoceranib and Camrelizumab combination therapy as a first-line treatment for liver cancer is expected by the PDUFA date of July 23, 2026; this major binary event is expected to have a high price impact expected

7/23/2026, 12:00:00 AM

Samchundang Pharm Co Ltd (000250) · Other

An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.

6/30/2026, 12:00:00 AM

Hansoh Pharmaceutical Group Company Limited (3692) · Other

Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.

6/26/2026, 12:00:00 AM

Innovent Biologics Inc (1801) · Other

Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected

6/4/2026, 12:00:00 AM